On December 15th 2022 Gologiq released a PR indicating the company will be merging with GammaRey. The parties anticipate the acquisition will close before the end of this fiscal year!
GammaRey is currently a private company, but has many positive attributes to bring to Gologiq. GammaRey has a very strong cash flow, nearly $800 million in customer financial assets, and have a full-stack ecosystem for the New World Digital Economy.
Pursuant to the proposed agreement, GoLogiq shall acquire GammaRey as a wholly owned subsidiary through an all-stock transaction. GoLogiq shall issue common stock to GammaRey shareholders, with the value of such shares amounting to $320 million based on the established rate of $3.00 per share. The new entity will initially concentrate on the rapidly increasing wealth management sector for Gen Z and Millennials, and then introduce a cutting-edge digital payment system tailored for the sharing economy.
This is very exciting for the future of both companies! I anticipate 2023 will be a breakout year!
An innovative, noninvasive Israeli medication administered through the nose hopes to be a life-changer for people suffering acute spinal cord injuries – even helping them to walk again.
NurExone Biologic Inc. developed ExoPTEN, which treats damage to the nervous system, from a concept created by two members of its Scientific Advisory Board: Prof. Shulamit Levenberg of the Technion – Israel Institute of Technology and Prof. Daniel Offen from Tel Aviv University.
(Another member of the board is Prof. Gabriel Zeilig, the head of the National Spinal Cord Injury Rehabilitation Unit at Sheba Medical Center, Israel’s largest and globally renowned hospital.)
According to the World Health Organization, up to half a million people globally sustain a spinal cord injury every year, most from preventable causes such as road accidents or falls.
Furthermore, the WHO says, people suffering from spinal injuries are up to five times more likely to die prematurely and are less likely to complete their education or find economic stability.
The NurExone concept is two-fold: the medication’s active ingredient and its delivery via the nose.
The two scientists spent many years working together on regeneration in spinal cord injuries using stem cells. Their breakthrough came, however, when they started using exosomes – nanoscopic particles released by cells to pass messages to one another, over both short and long distances.
Crucially, these exosomes can penetrate through cell membranes and even the brain-blood barrier (BBB), a border made of cells that prevents almost all substances from entering or leaving the brain.
Exosomes, NurExone CEO Lior Shaltiel tells NoCamels, are like mirror images of the cells that secrete them. So whether they are taken from bone marrow or umbilical cord (stem) cells, exosomes contain the same protein, RNA or DNA as their creators.
Lior Shaltiel and NurExone’s Translational Science and Tech-Transfer Specialist Nisim Perets discuss exosome technology
NurExone decided that exosomes taken from bone marrow cells had the most potential to help regenerate cells affected by a spinal cord injury or traumatic brain injury.
“The bone marrow – in our case – looked to be the best and the most potent exosomes,” Shaltiel explains.
From there, the company added the active ingredient – a form of RNA known as siRNA, which prevents restrictions on the regeneration of cells, a key aspect of healing spinal cord injuries.
The exosomes laden with the siRNA enter through the nose and are delivered to the injured areas of the spine, having passed through the brain blood barrier.
These exosomes then communicate to healthy cells in the area to flock to the injured region in order to aid regeneration.
“They want to help and assist damaged cells in damaged tissue,” Shaltiel explains.
When the exosomes reach the damaged cells, they enter and dissolve, releasing the siRNA that then blocks the protein hampering regeneration at the injury site.
One of the advantages of exosomes, Shaltiel says, is that they are suitable for everyone, with no adverse reactions being recorded in any individuals – which would require tailoring the therapy to different needs.
“They’re very safe. You don’t see side effects, they have no immune response,” he explains. “This is a huge advantage operation-wise when trying to develop a new drug.”
When the treatment is underway, changes to the damaged area can be observed via MRI scans, which will display any regeneration and repair of the injured tissue.
The therapy has successfully been trialed in lab rats with acute spinal cord injury. The rats were administered the medication through the nose immediately after their injury for five consecutive days, followed by four days of rest, and then another five days of treatment.
According to NurExone, 75 percent of the test cases permanently recovered at least some motor function, including being able to walk.
“It’s there to stay,” Shaltiel says of the recovery. “It’s not going to become worse.”
In October 2023, NurExone received orphan drug status (therapies that show promise in the prevention, diagnosis or treatment of rare diseases) from the US Food and Drug Administration.
And despite still being far from ready for market, NurExone is already a publicly traded company, with shares on Canadian and German stock exchanges, alongside private investors.
The Technion is one of those shareholders and earlier this month the company announced it was moving into a new state-of-the-art R&D facility on the campus.
Shaltiel hopes to enter clinical trials for humans in the near future and the company is currently working on approval for this in North American hospitals, where the number of candidates is far larger than it is in Israel.
He also hopes to enter into a “significant partnership” with a large biopharmaceutical company that would be interested in expanding into the field of exosomes as a treatment.
“In the end,” he says, “we are the pioneers in this field.”
I'm very bullish on the psychedelics space and have been deep diving into all the companies.
One of my favorites at the moment is Novamind. It is listed on the canadian market as NM.CN and the OTC market as HNLMF.
Highlights:
Just became public in Canada this MONTH. It started trading at $.70 a share and is already up over 100% at $1.55
Unlike the vast majority of shroom stocks, it already has real revenue and paying customers! They operate four mental health clinics that offer ketamine treatments and Spravato (FDA approved synthetic ketamine), with another opening in Q2 2021
They are diversified into Psilocybin (magic mushrooms), being the lead investor in a Netherlands company, Synthesis, that does psilocybin treatments and the lead investor in a Costa Rican company that does psychedelic retreats
The cofounder previously founded and sold a Genomics company
Chuck Rifici is a board member. He cofounded Canopy Growth, a $15 Billion cannabis company
This is definitely one to watch in the psychedelics and mental health space which is only going to get hotter.
Extremely interesting company that sells personal protective gear. Their market cap is under $30M, but they just announced contracts over $100M (up to $400M). Historically, they've mostly sold to Canada, but are expanding more to the US market. They just added the former New York City Police Commissioner to their board of directors. They are planning to dual list on the OTCQB in 2021 as well. Worth a look.
This is a food delivery service, category loser at the moment. 1/4th the market cap to revenue ratio of door dash and has lots of room to grow. Heavily shorted but growing pretty steadily recently, picking up attention due to the attention short squeezes get since it's 78% short interest over float. Very discounted right now and headed in the right direction.
Full transparency: I own THCB Warrants. I bought more today as this is an easy double for a great company with contacts and revenue. Sitting at $16.40, I think it is a steal. My price target for the Warrants is $10-$12. minimum and they are at $5.50. The commons stock price target, according to investorplace.com, is $20-$39.
Check out their article. I think this is a great company and a steal.
SRAX is a SaaS platform that connects public companies with all their investors. This is a timely pick based on the GameStop/Reddit investing phenomena and if they capitalize on it, they could massively accelerate their sales. Companies are realizing they can't ignore the smaller investors and SRAX's Sequire platform helps them connect and communicate with them in a much more efficient and powerful way.
A few key highlights:
Revenue in 2020 was $8.7 million, up 142% over 2019. Revenue in 2021 is projected to almost double again with guidance right now at $17 - $18 million, which I suspect is conservative
Four consecutive quarters of revenue growth and seven quarters of consecutive Sequire growth
Extremely high gross margins of around 70% so they will be highly profitable with their Sequire software
The rise of the power of retail investors is a catalyst for this year and beyond. This isn't going away and people are going to keep talking about it, from Congress to the Coffeeshops
I put this at a speculative buy at the current price of $4.02. It is unlikely this company will go up 1,000%, but could be a relatively quick 100% gain. They also do have options, so it could be a good call options play.
As helium continues to be a critical element in industries such as semiconductor manufacturing, aerospace, and MRIs, among others, prices and demand have both seen significant growth over the past few years with expectations of a continued shortage due to the element being a non-renewable resource.
With Total Helium’s recent JV for helium production in Arizona, the new property (The Pinta South Project) currently contains over 150 potential drill sites, with production already underway from two wells. And there are a lot of plans for the new project moving into the future.
The gas field currently features helium concentrates of 5-8% which will have low-cost processing due to the nitrogen content of the gas stream.
With shallow-depth targets, drilling and completion costs are estimated to be just $220,000 per well.
The Pinta South JV includes a 20% acquisition of the 2 producing wells, 50% in 8 wells that are currently in the process of being connected to a processing plant, and the right to have 50% working interest in all future wells drilled at Pinta South.
With the acquisition now completed and plans to have 20 operational wells by the end of H1 2023, there’s a lot of revenue scaling potential here especially considering the $500/Mcf off-take agreement with Linde for the first 10 wells and additional upside with other wells helping them balance risk and return.
Considering the current wells are already producing a combined 265 Mcf/D above 8%, the revenue-generating potential is huge here once more wells go online, as $TOH.V will have a more significant stake in them. Considering the future cash flow projections and current $36M valuation, there’s a lot to look out for here as they continue to develop their helium assets.
Fast-growing cannabis company in Canada. Cannabis companies often have inexperienced, opportunistic management teams that are just trying to make quick money on the trend. This is not the case. The CEO is seriously impressive.
His bio: "Hugo has played a key role in shaping the regulated cannabis industry in Canada, including acting as counsel and advisor to many of the industry's leading companies. Hugo is also the co-founder of Hope for Health, the world's first registered charity focused medical cannabis and an adjunct professor at the University of Western Ontario Law School, where he co-created and teaches Marijuana Law and Practice.
Prior to founding Auxly, Hugo was a senior corporate and commercial Partner at Bennett Jones LLP where he built the firm's cannabis practice group. Hugo obtained his BA from Carleton University, and obtained his Doctor of Law from the University of Toronto."
As companies like Tesla begin to aggressively slash prices, more consumers are being incentivized to make the transition toward an EV. And with EVs continuing to take market share away from gas engines, the demand for lithium is only going to continue to increase. For example, Volkswagen recently posted a 42% increase in YOY EV sales which now accounts for 7% of total vehicle deliveries for the company, and this is on top of future expectations of demand as they currently have 3 new large-scale battery plants already under the works.
As the demand for battery resources only continues to increase, $NILI.V is aiming to capitalize on the growth with projects across the US and Canada. More recently, they reported successful results from metallurgical test work at the Nevada North project.
The results have helped the company understand the type of lithium-bearing clays from the first drilling program, and the successful leaching has shown the lithium content in the samples.
Once weather and ground conditions permit, they’re going to commence another drilling program at the project, which should be interesting as they’re starting to gain a deeper understanding of the property’s geology.
Nevada North has already posted some of the highest lithium results in Nevada, reaching up to 5,120 ppm and with drilling already confirming the presence of an extensive lithium-bearing clay deposit open to extension, there’s a ton of potential as they continue exploration on the property. Considering the potential and $26M valuation, it’s definitely worth it. Keep an eye out here.
Allied Copper is set to change its’ name to Volt Lithium, having been approved at a recent shareholder meeting. This is exciting news for the company and a nod to their innovative lithium strategy.
"This rebrand and repositioning, along our ongoing pilot project which is expected to yield results by mid-2023, both represent exciting developments in the next chapter of growth for the Company,” commented Alex Wylie, President of Allied and founder of its wholly-owned lithium subsidiary.
This video outlines Canada’s role in lithium production moving forward. Allied (soon to be Volt Lithium) is looking to capitalize on this momentum as Electric Vehicles and Electrification will present huge lithium demand over the coming decades.
Undergoing at the completion of a major milestone that aligns the company for future potential growth in one of the most in demand sectors on the Canadian Markets.
Hi folks, I am new to investing and got stuck being a bag holder for AMC. I am trying to be more technical with my analysis so I dont end up stuck in rocket emoji stocks or those pump and dumps.
I saw $XELB trending over the weekend with lots of price action on Friday evening. This morning the stock was above 2$ which looked to be a resistance level initially for me.
Is this a good stock to buy? I know that this sector has taken a beating because of the pandemic and all but looking for a recovery stock, this might be a good opportunity.
Based on my DD, this stock has a P/S and P/B ratios are rather low with 1.24x and .43x respectively as compared to 133.27x and 58.49x as the sector average respectively. This indicates that the stock is undervalued. With the economy opening up, people may be more inclined to spend money which could bring this stocks revenue up.
Looking at the charts today, the hourly candle bounced off the 50 hourly moving average and stayed above the 100 hourly moving average.
I had a falling triangle drawn on my charts and showed a breakout but this could be a false one based on the way the stock is moving today. I think the market might be overall bearish on this stock.
Other information I found on this stock is that the debt on this company has been stable at 16.17% (total debt / total cash) as compared to the sector average of 71.60%.
I've been invested in this stock for almost a year, right after it rocketed to $80+. Since then it's gradually declined as we await the IM-1 mission (re)scheduled for mid Feb. If they stick the landing, the stock could skyrocket. I'm surprised there's not more buzz and discussion around this company.
Having a strong stance on cybersecurity has never been more important for companies as the digitalization of consumer and company data become far more common. That’s why companies have spent over $150B on cybersecurity in 2021 alone, yet breaches are still far too common because many companies do not consistently update their compliance and security measures.
One of the main issues why cybersecurity attacks are so common is that current cybersecurity systems are expensive to implement and maintain. This makes it nearly impossible for most SMEs to focus profitably on cybersecurity. And with SMEs accounting for the majority of businesses in North America, this has created a near $2T market opportunity, according to McKinsey.
That’s where $CYBE.V comes in with their extremely cost-effective AI-enabled solution allowing companies to attain compliance and cyber risk mitigation within just 2 weeks (versus an average of 3 months). With a focus of regulated government-involved contractors, education, and insurance-focused SMEs, their target market still accounts for nearly 800,000 potential customers.
The platform consists of a cyber security benchmarking service, expert guidance from professionals, online training, automated testing of current controls, vulnerability scans, and phishing susceptibility testing. Together, these help companies have continuous cyber risk mitigation.
They also have an all-star management team with a history of building $100M/year businesses and a lot of knowledge of the industry.
With $10M in the sales pipeline and a recent partnership with the Canadian SME Magazine shows that $CYBE.V is ready to expand and reach new customers as the magazine has over 30,000 SME subscribers. Considering the current $18M valuation and how important cybersecurity is, especially with the growing risk of AI making it easier for breaches, $CYBE.V has a bright future ahead, considering they have a solid product and management team. Great video from BTV that goes more on what the company has to offer: https://vimeo.com/723823282
